Loading
RP902 / Mild Cognitive Impairment (MCI) · Phase 2 Trial
ClinicalTrials.gov · August 3, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration for RP902, an investigational drug targeting AD-derived mild cognitive impairment. No results are posted in this registry record; the entry describes only the planned study protocol and has not yet begun recruitment.
Phase 2, Interventional, Randomized, Parallel, Quadruple masking, Treatment purpose. Mild Cognitive Impairment (MCI); age from 50 Years; to 85 Years. Intervention: RP902 low dose group; RP902 high dose group. Compared with: Placebo — Placebo Comparator. n = 360. Approximately 50 sites in China.
This is a Phase 2 trial registration for RP902, an investigational drug targeting AD-derived mild cognitive impairment. No results are posted in this registry record; the entry describes only the planned study protocol and has not yet begun recruitment.
No efficacy, safety, or comparative data are reported in this registry record.
Clinicians and researchers should note this is a planned Phase 2 study with no efficacy or safety data yet available. The trial is not yet recruiting, and results will be needed to assess any clinical relevance of RP902 for MCI.
Phase 2 trial of an unapproved investigational drug in MCI with no results yet reported; registration describes planned conduct only.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and researchers should note this is a planned Phase 2 study with no efficacy or safety data yet available. The trial is not yet recruiting, and results will be needed to assess any clinical relevance of RP902 for MCI.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07579884). This is a study registration, not published results. Lead sponsor: Risen (Suzhou) Pharma Tech Co., Ltd.. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 360 participants (ESTIMATED). Conditions: Mild Cognitive Impairment (MCI). Interventions: DRUG: RP902; DRUG: Placebo. Primary outcome measures: Clinical Dementia Rating Scale - Sum of Boxes , Week 48. Brief summary: The purpose of the study is to evaluate the preliminary efficacy of RP902 Tablets in participants with Alzheimer's disease (AD)-derived mild cognitive impairment (MCI) and provide a design basis for the Phase III study. This Phase II study plans to enroll 360 participants and will be conducted at approximately 50 sites in China. The study consists of a Screening Period (up to 4 weeks) and a double-blind treatment period (48 weeks). After completing the 48-week double-blind treatment period, participants may choose to continue into an extension treatment period (96 weeks) or undergo safety follow-up (4 weeks after the last dose).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.